Alphapharm Pty Ltd v H Lundbeck A/S (No 2)

Link copied
Case Copied 21 min read

FEDERAL COURT OF AUSTRALIA

Alphapharm Pty Ltd v H Lundbeck A/S (No 2) [2008] FCA 1036

COSTS – four proceedings heard together – meaning of “costs following the event” – costs order made on a broad issues basis, but “event” in each proceeding taken into account.

PATENTS – order for removal of particulars of extension of term from Register of Patents – whether Court would have power to order reinstatement of particulars if patentee’s appeal should succeed.

Held:  there is at least some doubt as to whether Court has that power, and in view of hardship that patentee would suffer if Court lacks the power, the order for rectification of Register should be stayed.

Patents Act 1990 (Cth) s 192

Atlantis Corporation Pty Ltd v Schindler, unreported, Emmett J, 27 May 1997 cited
Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495 cited
Imperial Chemical Industries plc v E I Dupont De Nemours & Co (2002) 58 IPR 227 cited
Woolworths Ltd v BP plc (2006) 150 FCR 134 referred to
Hughes v Western Australian Cricket Association (Inc) (1986] ATPR 40-748 cited
Bowen Investments Pty Ltd v Tabcorp Holdings Ltd (No 2) [2008] FCAFC 107 cited

ALPHAPHARM PTY LTD (ACN 002 359 739) v
H LUNDBECK A/S AND LUNDBECK AUSTRALIA PTY LTD (ACN 070 094 290)
NSD 1120 OF 2005

ARROW PHARMACEUTICALS PTY LTD (ACN 003 144 170) v

H LUNDBECK A/S
NSD 954 OF 2006

H LUNDBECK A/S v COMMISSIONER OF PATENTS AND
ALPHAPHARM PTY LTD
NSD 1078 OF 2006

LINDGREN J
10 JULY 2008
SYDNEY



IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

NSD 1120 OF 2005

BETWEEN:

ALPHAPHARM PTY LTD (ACN 002 359 739)
Applicant/Cross-respondent

AND:

H LUNDBECK A/S
Respondent/First Cross-Claimant

LUNDBECK AUSTRALIA PTY LTD (ACN 070 094 290)
Second Cross-claimant

JUDGE:

LINDGREN J

DATE OF ORDER:

19 JUNE 2008

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The Applicant/Cross-Respondent (Alphapharm) has, between November 2002 and 27 May 2004, infringed each of claims 1, 3 & 6 of Australian Patent No 623144 (the Patent).

2.Alphapharm be permanently restrained whether by itself, its directors, servants, agents or otherwise howsoever during the term of the Patent, from exploiting the Patent or authorising others to do so, save as permitted by s 78 or s 119A of the Patents Act1990 (the Act).

2A.Upon the Respondents/Cross Claimants (Lundbeck) giving the undertaking in 12 below and until further order of the Court, Alphapharm be restrained whether by itself, its directors, servants, agents or otherwise howsoever during the term of any extension of the Patent, from exploiting the Patent or authorising others to do so save as permitted by s 78 or s 119A of the Act.

3.The District Registrar draw up and issue a certificate pursuant to s 19(1) of the Act certifying that the validity of each of claims 1, 2, 3, 4 and 6 of the Patent was questioned, provided that no such certificate be issued before the expiry…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Alphapharm Pty Ltd v H Lundbeck A/S (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2008] FCA 1036
Decision Date

CaseChat Overview and Summary

In the case of Alphapharm Pty Ltd v H Lundbeck A/S (No 2), the primary legal issue before the court was whether a permanent injunction should be ordered against Alphapharm to prevent it from exploiting a patent owned by H Lundbeck A/S. The court was also required to decide if it had the power to order the reinstatement of particulars of an extension of term in the Register of Patents if H Lundbeck A/S's appeal was successful. The dispute centred around the validity and infringement of certain claims of a patent related to the drug escitalopram. The court found that Alphapharm had infringed specific claims of the patent and that a permanent injunction was necessary to prevent further exploitation of the patent by Alphapharm, except as permitted by certain sections of the Patents Act 1990. Additionally, the court held that it had the power to order the reinstatement of particulars of the extension of term in the Register of Patents if H Lundbeck A/S's appeal was successful, and therefore granted a stay on the removal of these particulars.

The court's reasoning was based on the need to balance the interests of both parties. While it recognised that H Lundbeck A/S was willing to accept an undertaking from Alphapharm pending trial, this should not preclude it from seeking a permanent injunction if an agreement could not be reached. The court also determined that there was some doubt about its power to order the reinstatement of particulars of the extension of term in the Register of Patents, and therefore granted a stay on the removal of these particulars to prevent potential injustice to H Lundbeck A/S if its appeal was successful. The court emphasised the importance of ensuring that any decision did not cause significant harm to either party and aimed to maintain a fair and balanced approach in its rulings. The final orders included a permanent injunction against Alphapharm, a stay on the removal of particulars of the extension of term, and provisions for costs and damages to be assessed and paid by Alphapharm.

Orders

Orders of the court

1. The Applicant/Cross-Respondent (Alphapharm) has, between November 2002 and 27 May 2004, infringed each of claims 1, 3 & 6 of Australian Patent No 623144 (the Patent).

2. Alphapharm be permanently restrained whether by itself, its directors, servants, agents or otherwise howsoever during the term of the Patent, from exploiting the Patent or authorising others to do so, save as permitted by s 78 or s 119A of the Patents Act 1990 (the Act).

2A. Upon the Respondents/Cross Claimants (Lundbeck) giving the undertaking in 12 below and until further order of the Court, Alphapharm be restrained whether by itself, its directors, servants, agents or otherwise howsoever during the term of any extension of the Patent, from exploiting the Patent or authorising others to do so save as permitted by s 78 or s 119A of the Act.

3. The District Registrar draw up and issue a certificate pursuant to s 19(1) of the Act certifying that the validity of each of claims 1, 2, 3, 4 and 6 of the Patent was questioned, provided that no such certificate be issued before the expiry of 42 days from the date of making of these Orders or, if an appeal or cross-appeal against this Order is filed within that period, until after the determination of that appeal or cross-appeal.

4. Claim 5 of the Patent is and has at all material times been invalid.

5. Claim 5 of the Patent be revoked.

6. The Register of Patents (the Register) be rectified pursuant to s 192 of the Act to remove the extension of term of the Patent from the Register.

7. Upon Lundbeck giving the undertakings in 12 and 13 below, Orders of paras 5 and 6 above be stayed:

(a) initially until the date which is 21 days after the making of these Orders; and

(b) if a notice of appeal to the Full Court of the Federal Court is filed against those Orders within that period, until the determination of that appeal.

8. Alphapharm give discovery, verified by affidavit, by the date which is 42 days after the making of these Orders of all documents relating to any importation, manufacture, use, sale, other disposal or offer to manufacture, sell or otherwise dispose of, prior to 27 May 2004, a product which is or contains escitalopram.

9. Alphapharm pay the Respondents’/Cross-claimants’ damages for infringement of the Patent, to be assessed on a date to be fixed.

10. The Orders of para 8 and 9 above be stayed:

(a) initially until the date which is 21 days after the making of these Orders; and

(b) if a notice of appeal to the Full Court of the Federal Court is filed within that period, until the determination of that appeal.

11. Alphapharm pay 30 percent of the Respondents’/Cross-claimants’ costs of proceedings NSD 1120 of 2005 and NSD 954 of 2006.

THE COURT NOTES:

12. Lundbeck undertakes to the Court:

(a) to pay to Alphapharm such damages or loss whether legally claimable or not as a Judge may think just and fair as compensation to Alphapharm for any disadvantage it may sustain by reason of Orders of paras 2A and 7 above;

(b) to have particulars of the Orders of paras 4 to 7 above registered pursuant to s 187 of the Act;

(c) until the final determination of any appeal, not to threaten any person with infringement of claim 5 of the Patent; and

(d) not to seek to amend any claim of the Patent otherwise than in the course of or in connection with proceedings in this Court.

13. Lundbeck undertakes to the Court during the period of the stay set out in Order 7 to prosecute any appeal expeditiously.

1. The District Registrar draw up and issue a certificate pursuant to s 19(1) of the Patents Act 1990 (Cth) certifying that the validity of each of claims 1, 2, 3, 4 and 6 of Australian Patent No 623144 (the Patent) was questioned, provided that no such certificate be issued before the expiry of 42 days from the date of making of these Orders or, if an appeal or cross-appeal against this Order is filed within that period, until after the determination of that appeal or cross-appeal.

2. Claim 5 of the Patent is and has at all material times been invalid.

3. Claim 5 of the Patent be revoked.

4. The Register of Patents (the Register) be rectified pursuant to s 192 of the Act to remove the extension of term of the Patent from the Register.

5. Upon the Respondent giving the undertakings in paras 7 and 8 below, Orders of paras 3 and 4 above be stayed:

(a) initially until the date which is 21 days after the making of these Orders; and

(b) if a notice of appeal to the Full Court of the Federal Court is filed against those Orders within that period, until the determination of that appeal.

6. The Applicant pay 10 percent of the Respondent’s costs of proceedings NSD 1120 of 2005 and NSD 954 of 2006.

THE COURT NOTES:

7. The Respondent undertakes to the Court:

(a) to pay to the Applicant such damages or loss whether legally claimable or not as a Judge may think just and fair as compensation to the Applicant for any disadvantage it may sustain by reason of Order of para 5 above;

(b) to have particulars of the Orders of paras 2 to 5 above registered pursuant to s 187 of the Act;

(c) until the final determination of any appeal, not to threaten any person with infringement of claim 5 of the Patent; and

(d) not to seek to amend any claim of the Patent otherwise than in the course of or in connection with proceedings in this Court.

8. The Respondent undertakes to the Court during the period of the stay set out in Order 5 to prosecute any appeal expeditiously.

1. The appeal be dismissed.

2. The Commissioner correct the Register of Patents by removing from it the extension of term of Australian Patent No 623144.

3. Upon the Applicant giving the undertakings in paras 7 and 8 below, the Order of para 2 above be stayed:

(a) initially until the date which is 21 days after the making of these Orders; and

(b) if a notice of appeal is filed to the Full Court of the Federal Court within that period, until the determination of that appeal.

4. The Applicant be granted leave to appeal to the Full Court by filing a notice of appeal by the date which is 21 days after the making of these Orders.

5. Pursuant to Order 1 rule 8 of the Federal Court Rules, compliance with Order 52, Division 1, be dispensed with.

6. The Applicant pay the First and Second Respondents’ costs of the proceeding.

AND THE COURT NOTES:

7. The Applicant undertakes to the Court:

(a) to pay to the Respondents such damages or loss whether legally claimable or not as a Judge may think just and fair as compensation to the Respondents for any disadvantage they may sustain by reason of the Order of para 3 above;

(b) to have particulars of the Orders of paras 2 and 3 above registered pursuant to s 187 of the Patents Act 1990; and

(c) not to seek to amend any claim of the Patent otherwise than in the course of or in connection with proceedings in this Court.

8. The Applicant undertakes to the Court during the period of the stay set out in Order 3 to prosecute any further appeal expeditiously.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

LINDGREN J
There was an issue as to whether a permanent injunction should be ordered against Alphapharm. Alphapharm submitted that Lundbeck should be satisfied, as it had been in the past, with Alphapharm’s undertaking. However, the fact that Lundbeck was willing to accept an undertaking pending trial should not deprive it of the right to seek a permanent injunction in the absence of agreement on an undertaking. There should be a permanent injunction restraining Alphapharm from exploiting the Patent save as allowed by s 78 (or now s 119A) of the Act.CONCLUSION The reasons set out above are the reasons why I made the orders in the three proceedings mentioned on 19 June 2008.

Ratio Decidendi

Legal Principle Established

Established by: LINDGREN J

As referred to below, other issues were also in contest.CONSIDERATIONThe question of a stay On the stay question two issues were raised: (1) will there be time for any appeal to be heard and determined by 13 June 2009, when the original term of the Patent will expire?; and (2) does the Court have power to reinstate the entry of the particulars of the extension of term in the event that Lundbeck’s appeal is successful? Alphapharm and Arrow accept that, upon the appropriate undertakings being given by Lundbeck, there should be a stay in relation to revocation of claim 5 of the Patent since there is some doubt as to the Court’s power to order re-instatement: see Atlantis Corporation Pty Ltd v Schindler, unreported, Emmett J, 27 May 1997; Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495 at [4]; Imperial Chemical Industries plc v E I Dupont De Nemours & Co (2002) 58 IPR 227 at [11]. I agree that there should be a stay in relation to claim 5. I note that in Doric v Lockwood above, Hely J observed (at [4]) that it is usual for an order for revocation of a patent to be stayed pending an appeal against the order. However, both Alphapharm and Arrow contend that there should be no stay in relation to removal of the particulars of the extension of the term of the Patent, and that no such doubt exists in relation to the Court’s power to order re-instatement of those particulars. The extension granted was from and including 14 June 2009 to 13 June 2014. If Lundbeck’s appeal succeeds in relation to the extension, it will be held that it was entitled to retain that extension. Immediate removal of the particulars will tell the world now that the term of the Patent will not extend beyond 13 June 2009, and other pharmaceutical and generic companies may make plans and expenditures on the faith of the removal. I was informed that if there is a stay, nonetheless the attention of those searching the Register will be drawn to the fact of the making of the Court’s orders, the pending appeal and the stay of the orders in the light of the appeal. If the particulars of the extension are removed, and the Court lacks power to order their reinstatement, Lundbeck would suffer a gross injustice if it succeeds in its appeal, whether or that success occurs before or after 13 June 2009. Obviously it would be a very serious matter for Lundbeck to be denied the benefit of such success merely because the Court lacked power to order reinstatement of the registration of the extension. On the other hand, if the particulars of the extension remain registered and Lundbeck loses the appeal after 13 June 2009, Lundbeck will have the benefit of a de facto extension for a short while beyond that date. From Alphapharm’s viewpoint, Alphapharm would not enjoy the benefit of the removal of the particulars of the extension until after 13 June 2009. However, if Lundbeck’s appeal is dismissed at some time later than 13 June 2009, the effect of the stay will be to deprive Alphapharm of the fruits of its victory at first instance in relation to the period from that date to the dismissal of the appeal.